Chronic exposure to the gibberellin derivative GA‑13315 sensitizes breast cancer MCF‑7 cells but not colon cancer HCT116 cells to irinotecan

Cheng,Xianliang; Wang,Guohui; Liao,Yuan; Mo,Jiao; Qing,Chen

doi:10.3892/ol.2020.12144

Chronic exposure to the gibberellin derivative GA‑13315 sensitizes breast cancer MCF‑7 cells but not colon cancer HCT116 cells to irinotecan

Authors:
- Xianliang Cheng
- Guohui Wang
- Yuan Liao
- Jiao Mo
- Chen Qing
View Affiliations

Affiliations: School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan 650500, P.R. China
Published online on: September 23, 2020 https://doi.org/10.3892/ol.2020.12144
Article Number: 281
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

13‑Chlorine‑3,15‑dioxy‑gibberellic acid methyl ester (GA‑13315) is a gibberellin derivative that exhibits selective cytotoxicity to multidrug resistant MCF‑7/ADR cells and reverses drug resistance when administered at subtoxic doses in combination with chemotherapy drugs. The present study aimed to investigate the impact of chronic GA‑13315 exposure on the chemosensitivity of MCF‑7 and HCT116 cell lines. Cells were administered a subtoxic dose of 1 µM GA‑13315 for 12 weeks and the sensitivity of the cells to GA‑13315, irinotecan and cisplatin, was assessed. The Cell Counting Kit‑8 assay results demonstrated that the chronic exposure did not induce resistance to GA‑13315, in either MCF‑7 or HCT116 cells. Notably, MCF‑7 cells were sensitized to irinotecan following exposure to GA‑13315; however, HCT116 cells were not. The sensitizing effect of GA‑13315 was associated with the alterations of topoisomerase 1 (Top1) protein expression, tyrosyl DNA phosphodiesterase 1 and checkpoint kinase 1. Further analysis indicated that GA‑13315 caused DNA fragmentation; however, DNA damage was not mediated by a Top1‑dependent molecular mechanism, as GA‑13315 was revealed not to be a Top1 poison, despite inhibiting the catalytic activity of Top1. Taken together, the results of the present study indicated that GA‑13315 may be used for sensitizing MCF‑7 cells to irinotecan, as the chronic exposure of GA‑13315 to MCF‑7 cells still showed sensitizing effects to irinotecan.

View Figures

View References

1	Schoeffler AJ and Berger JM: DNA topoisomerases: Harnessing and constraining energy to govern chromosome topology. Q Rev Biophys. 41:41–101. 2008.PubMed/NCBI
2	Li TK and Liu LF: Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 41:53–77. 2001.PubMed/NCBI
3	Wu CP, Calcagno AM and Ambudkar SV: Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr Mol Pharmacol. 1:93–105. 2008.PubMed/NCBI
4	Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA and Fisher RI; Southwest Oncology Group, : Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol. 21:1996–2003. 2003.PubMed/NCBI
5	Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al: Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 17:286–301. 2017.PubMed/NCBI
6	Johnson BE: Concurrent approaches to combined chemotherapy and chest radiotherapy for the treatment of patients with limited stage small cell lung cancer. Lung Cancer. 10 (Suppl 1):S281–S287. 1994.PubMed/NCBI
7	Zhu Y, Liu C, Armstrong C, Lou W, Sandher A and Gao AC: Antiandrogens inhibit ABCB1 Efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer. Clin Cancer Res. 21:4133–4142. 2015.PubMed/NCBI
8	Palmeira A, Sousa E, Vasconcelos MH and Pinto MM: Three decades of P-gp inhibitors: Skimming through several generations and scaffolds. Curr Med Chem. 19:1946–2025. 2012.PubMed/NCBI
9	Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 370:153–164. 2016.PubMed/NCBI
10	Yuan H, Li X, Wu J, Li J, Qu X, Xu W and Tang W: Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr Med Chem. 15:470–476. 2008.PubMed/NCBI
11	Bomke C and Tudzynski B: Diversity, regulation, and evolution of the gibberellin biosynthetic pathway in fungi compared to plants and bacteria. Phytochemistry. 70:1876–1893. 2009.PubMed/NCBI
12	Chen J, Sun Z, Zhang Y, Zeng X, Qing C, Liu J, Li L and Zhang H: Synthesis of gibberellin derivatives with anti-tumor bioactivities. Bioorg Med Chem Lett. 19:5496–5499. 2009.PubMed/NCBI
13	Zhang Y, Zhang H, Chen J, Zhao H, Zeng X, Zhang H and Qing C: Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative. Invest New Drugs. 30:8–16. 2012.PubMed/NCBI
14	Mo J, Kang M, Ye JX, Chen JB, Zhang HB and Qing C: Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1. Cancer Chemother Pharmacol. 78:51–61. 2016.PubMed/NCBI
15	Das SG, Hermanson DL, Bleeker N, Lowman X, Li Y, Kelekar A and Xing C: Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4- (2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): A novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy. ACS Chem Biol. 8:327–335. 2013.PubMed/NCBI
16	Walker JM: The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol. 32:5–8. 1994.PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI
18	Sabisz M, Wesierska-Gadek J and Skladanowski A: Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. Biochem Pharmacol. 79:1387–1397. 2010.PubMed/NCBI
19	Patra N, De U, Kang JA, Kim JM, Ahn MY, Lee J, Jung JH, Chung HY, Moon HR and Kim HS: A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. Eur J Pharmacol. 658:98–107. 2011.PubMed/NCBI
20	Champoux JJ: DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem. 70:369–413. 2001.PubMed/NCBI
21	Peterson KE, Cinelli MA, Morrell AE, Mehta A, Dexheimer TS, Agama K, Antony S, Pommier Y and Cushman M: Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: Investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. J Med Chem. 54:4937–4953. 2011.PubMed/NCBI
22	Chen AY and Liu LF: DNA topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 34:191–218. 1994.PubMed/NCBI
23	Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077–5082. 1989.PubMed/NCBI
24	Liu LF, Desai SD, Li TK, Mao Y, Sun M and Sim SP: Mechanism of action of camptothecin. Ann NY Acad Sci. 922:1–10. 2000.PubMed/NCBI
25	Irinotecan, . Drugs and Lactation Database (LactMed) National Library of Medicine (US). Bethesda, MD: 2006
26	Gilbert DC, Chalmers AJ and El-Khamisy SF: Topoisomerase I inhibition in colorectal cancer: Biomarkers and therapeutic targets. Br J Cancer. 106:18–24. 2012.PubMed/NCBI
27	Li F, Jiang T, Li Q and Ling X: Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am J Cancer Res. 7:2350–2394. 2017.PubMed/NCBI
28	El-Khamisy SF, Hartsuiker E and Caldecott KW: TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks. DNA Repair (Amst). 6:1485–1495. 2007.PubMed/NCBI
29	El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, Lupski JR and Caldecott KW: Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature. 434:108–113. 2005.PubMed/NCBI
30	Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, et al: Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol. 81:179–229. 2006.PubMed/NCBI
31	Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM and Smythe C: Activation of mammalian Chk1 during DNA replication arrest: A role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol. 154:913–923. 2001.PubMed/NCBI
32	Zachos G, Rainey M and Gillespie DA: Lethal errors in checkpoint control-life without Chk1. Cell Cycle. 2:14–16. 2003.PubMed/NCBI
33	Liu C, Zhou S, Begum S, Sidransky D, Westra WH, Brock M and Califano JA: Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer. 55:303–311. 2007.PubMed/NCBI
34	Dean RA, Fam HK, An J, Choi K, Shimizu Y, Jones SJ, Boerkoel CF, Interthal H and Pfeifer TA: Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays. J Biomol Screen. 19:1372–1382. 2014.PubMed/NCBI
35	Pommier Y and Cushman M: The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: Update and perspectives. Mol Cancer Ther. 8:1008–1014. 2009.PubMed/NCBI
36	Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F and Abraham RT: Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell. 19:607–618. 2005.PubMed/NCBI
37	Walensky LD: BCL-2 in the crosshairs: Tipping the balance of life and death. Cell Death Differ. 13:1339–1350. 2006.PubMed/NCBI
38	Tsukahara S, Yamamoto S, Tin-Tin-Win-Shwe, Ahmed S, Kunugita N, Arashidani K and Fujimaki H: Inhalation of low-level formaldehyde increases the Bcl-2/Bax expression ratio in the hippocampus of immunologically sensitized mice. Neuroimmunomodulation. 13:63–68. 2006.PubMed/NCBI
39	Xu C, Xu W, Palmer AE and Reed JC: BI-1 regulates endoplasmic reticulum Ca2⁺ homeostasis downstream of Bcl-2 family proteins. J Biol Chem. 283:11477–11484. 2008.PubMed/NCBI
40	Lo YL and Liu Y: Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides. PLoS One. 9:e901802014.PubMed/NCBI
41	Liaud N, Horlbeck MA, Gilbert LA, Gjoni K, Weissman JS and Cate JHD: Cellular response to small molecules that selectively stall protein synthesis by the ribosome. PLoS Genet. 15:e10080572019.PubMed/NCBI
42	Watters DJ: Ascidian toxins with potential for drug development. Mar Drugs. 16:1622018.
43	Pavitt GD: Regulation of translation initiation factor eIF2B at the hub of the integrated stress response. Wiley Interdiscip Rev RNA. 9:e14912018.PubMed/NCBI